Product Description
Nazartinib is a potent, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. It covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling.
Nazartinib is a potent, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. It covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling.
Biovision | B2288 | Nazartinib DataSheet
Alternate Name/Synonyms: (R,E)-N-(7-chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide; EGF816; NSV816
Appearance: White to off-white solid
Formulation: N/A
CAS Number: 1508250-71-2
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₆H₃₁lN₆O₂
Molecular Weight: 495.02
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor
MDL Number: N/A
PubChem CID: 72703790
SMILES: CC1=NC=CC(=C1)C(=O)NC2=NC3=C(N2C4CCCCN(C4)C(=O)C=CCN(C)C)C(=CC=C3)Cl
InChi: InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33(26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5,8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1
InChi Key: IOMMMLWIABWRKL-WUTDNEBXSA-N